The PATHFAST Analyzer helps accelerate urgent cardiac care decisions in the emergency department with reliable, lab-quality testing at the point of care.
With the PATHFAST Education & Resources Center, we provide materials to help clinicians identify urgent cardiac concerns sooner, accelerate diagnosis, and ultimately improve the patient experience.
Presented by Ashlee Tezak, Manager of the Presbyterian Point of Care program
FSEDs and hybrid FSED/urgent care centers are facing increasing pressure to deliver rapid, high-quality diagnostics while managing staffing constraints, maintaining compliance, and ensuring consistent workflows across decentralized settings. This webinar will address these challenges by showing how a structured point-of-care testing program can support moderately complex testing, standardize operations, reduce turnaround times, and improve coordination between clinical and laboratory teams. Attendees will walk away with practical strategies for test menu design and integrating cardiac biomarkers into a broader POCT strategy to enable faster, more confident clinical decision- making.
Presented by Dr Todd Kelley, Pathologist
Dr Kelley shares lab-focused insights on quality control, POC implementation, and coordinating with central lab workflows.
Presented by Dr James McCord, MD
Hear Dr McCord discuss the clinical value of hsTnI in diagnosing MI, serial testing, post-cath decisions, and what the future holds for this biomarker.
Presented by Dr Sean-Xavier Neath, MD, PhD, FACEP
We are excited to share our latest educational podcast featuring Dr. Neath, MD, FACEP, discussing the implementation of point-of-care high-sensitivity troponin I (hsTnI) assays in U.S. emergency departments.
In this insightful conversation with Christina Wichmann, Editor in Chief of Medical Laboratory Observer, Dr. Neath explores:
Polymedco presents “Exploring challenges and opportunities in emergency care: The potential of POC cardiac assays with Dr Robert Christenson.” This Q&A focuses on the challenges faced in quickly assessing and ruling out cardiac events, and how point-of-care (POC) assays from the PATHFAST Analyzer can help transform emergency cardiac care.
Explore the potential of the first FDA-cleared POC hs-cTn assay with Dr Christenson.
Presented by Dr James McCord, MD
In this webinar, Dr. James McCord, an experienced cardiologist and thought leader in cardiac diagnostics, will discuss how hsTnI testing at the point of care is transforming risk stratification in both hospital and outpatient environments. Using real-world examples and clinical insights, he will address common misconceptions, serial testing strategies, and how POC access to hsTnI can support decision-making in freestanding EDs and urgent care centers.
Presented by James Januzzi, MD and Ioana Preston, MD
James Januzzi, MD
Adolph Hutter Professor of Medicine; Chief Scientific Officer and C. Michael Gibson Chair; Staff Cardiologist Harvard Medical School; Baim Institute for Clinical Research; Massachusetts General Hospital
Ioana Preston, MD
Director, Pulmonary Hypertension Center; Pulmonologist, Department of Pulmonary and Critical Care Medicine; Lahey Hospital and Medical Center
Join leading experts as they dive into the latest evidence on NT-proBNP’s role in:
Presented by Pedro Lopez Ayala, MD MS
Get the insights you need to confidently interpret and implement hs-cTn testing.
At the end of this webinar, you will understand:
Presented by Simon A. Mahler, MD, MS, FACEP
This webinar will discuss approaches to improve chest pain risk stratification using point-of-care diagnostics. Specifically, we will discuss high-sensitivity troponin, d-dimer, and natriuretic peptide biomarker testing and the advantages of point-of-care testing. This will include discussion of evidence-based algorithms that can be used to integrate these point-of-care biomarkers into the Emergency Department workflow.
Presented by Luca Koechlin, MD
Learn more about the clinical use of high-sensitivity cardiac troponin (hs-cTn) in early myocardial infarction diagnosis. Learn how hs-cTn assays differ in the US compared to outside of the US, understand the impact of FDA regulations on clinical applications, and explore the latest evidence on point-of-care hs-cTn assays in the webinar led by Dr Luca Koechlin, MD.
Presented by Dr Sean-Xavier Neath, MD, PhD, FACEP
How can point-of-care biomarkers accelerate diagnoses and transform patient outcomes in emergency departments? In this engaging session, Dr Neath dives into how POC biomarkers can help rapidly differentiate between life-threatening conditions, streamline ED workflows, and improve patient outcomes.
Presented by Robert H Christenson, PhD, DABCC, FADLM, FACC
This must-see industry workshop will highlight how POC high-sensitivity cardiac troponin (cTn) testing can improve patient and caregiver satisfaction, save system resources, and add value to laboratory medicine services.
Presented by Christopher R. deFilippi, MD, FACC, Inova Heart and Vascular Institute
Explore the crucial role of NT-proBNP in diagnosing and managing heart failure (HF). Learn about the implications of NT-proBNP levels in the context of renal disease, obesity, and other cardiovascular conditions, and how these levels guide treatment decisions, including the use of sacubitril-valsartan. This session aims to enhance understanding of NT-proBNP’s diagnostic value and its impact on optimizing patient care in heart failure management. This webinar will offer a great learning opportunity for healthcare professionals seeking to deepen their knowledge in managing HF diagnosis, prognostic, and risk assessment.
Presented by Fred Apple, PhD, Professor, University of Minnesota School of Medicine
In partnership with:
This webinar will review the latest evidence-based practices surrounding hs-cTn testing, offering insights into assay requirements, result interpretation, clinical integration, and more
High-sensitivity cardiac troponin I testing on the PATHFAST analyzer
Learn more about troponin as a biomarker of cardiac injury and discover how PATHFAST hs-cTnI-II can help improve outcomes for patients with suspected acute myocardial infarction (AMI).
